A clinical study on the safety of dendritic cell vaccine pulsed with neoantigen peptides for malignant tumor.
Phase 1
- Conditions
- Malignant tumor
- Registration Number
- JPRN-UMIN000032981
- Lead Sponsor
- KOUSHIKAI,Non-profitmedicalcorporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
A patient MUST NOT: 1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. 2)Have a history of a serious drug allergy. 3)Have a positive result of HIV antibody. 4)Have a serious cardiac disorder. 5)Have an active autoimmune disorder. 6)Have a concurrent cancer. 7)Have an infectious disorder that is difficult to control. 8)Be a female who is pregnant, lactating, or with a possibility of pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method